Tagged with

Global In conversation at ESMO 2024 in Barcelona, Astellas Chief Medical Officer Tadaaki Taniguchi lays out some of the company’s most promising recent oncology data, his hopes around how Astellas’ modality-based strategy will ultimately bring “meaningfully differentiated” therapies to patients, and why next-generation treatments stand to reshape the cancer care paradigm.…

Mexico Hernán Porcile, General Manager of Takeda Mexico, discusses the company’s innovative therapies, regulatory strategies, and the integration of ” “Takeda-ism” within the Mexican cultural context. He emphasizes Takeda’s commitment to sustainability, diversity, and collaboration with local healthcare ecosystems.   Respecting our legacy as a Japanese company while adapting to the…

Switzerland Hans Peter Borger of Spirig HealthCare discusses the company’s integration with the STADA Group and its focus on generics, consumer healthcare, and specialty markets, including Parkinson’s and rare diseases. He emphasises the importance of a growth mindset and a value-driven culture in navigating Switzerland’s regulatory landscape.   We are committed…

France In conversation at ESMO 2024, Pierre Fabre’s R&D Head Francesco Hofmann outlines some of the key data readouts for the company’s oncology portfolio from this year’s conference, how it is looking to expand its R&D portfolio via business development deals and biotech partnerships, and the spaces in which a mid-sized…

Mexico Oswaldo Bernal explains how Mexico is BMS’ top-performing market in Latin America (outside of Brazil) and plays a significant role in the company’s global growth strategy. He also discusses how Mexican patients face hurdles in accessing new treatments due to low health investment and lengthy regulatory approval processes, as well…

USA Troubled gene sequencing firm Illumina has announced a new strategy to accelerate growth. Under the leadership of CEO Jacob Thaysen, Illumina hopes to turn the page on a recent history marked by antitrust issues following its decision to acquire former spin-off company Grail.   Illumina’s ambitious new strategy comes after…

Switzerland Ernst Niemack, managing director of vips, the association representing pharmaceutical companies operating in Switzerland, comments on the government’s latest cost containment measures such as mandatory rebates and new rules for biosimilars and generics, and the impact of these policies on innovative pharma. He also discusses the lag between registrations and…

Switzerland After heading up AstraZeneca Switzerland for one year, Florian Saur reflects on his career journey, discusses the Swiss market and how the country, despite its advanced healthcare and research ecosystem, has fallen behind in terms of access to innovation and digitalization. He shares the ambitious plans to launch 35 new…

Mexico The French Chamber of Commerce in Mexico (CCI France Mexico) has been helping French companies such as Sanofi, Servier and Pierre Fabre establish themselves in Mexico for 140 years. General manager Hajer Najjar outlines how the CCI supports French investment in Mexico and promotes Mexican exports to France, and reviews…

China The R&D-Based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment (CAEFI) represents 46 multinational pharmaceutical companies with a strong R&D presence in China. Managing Director Renaud Gabay discusses how member companies are leveraging synchronized approvals to accelerate access; the evolution of China’s regulatory framework that…

Switzerland Swiss Biotech’s Michael Altorfer explains how Switzerland’s biotech industry continues to grow, driven by startups and SMEs and supported by strong international collaborations across the entire value chain. He outlines how Swissmedic’s proactive approach to advanced therapies and participation in the Access Consortium enables faster and more efficient drug approval…

Europe This year’s European Society of Medical Oncology (ESMO) was the largest ever. Over 33,000 people attended ESMO Congress 2024 at Barcelona’s cavernous Fira Gran Via conference centre, where 5,000 abstracts were presented and 600 expert speakers took to the stage. The healthcare professionals and cancer drug developers in attendance were…